This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Sign In
Don’t have an account?
  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Bayer cross
BAYER FOR PROFESSIONALSYour Resource Portal
  • Ophthalmology
  • EYLEA® (aflibercept) 8 mg
  • EYLEA® (aflibercept) 2 mg
  • Oncology
  • Nubeqa® (darolutamide)
  • Xofigo®▼ (radium-223 dichloride)
  • Cardiology
  • Beyonttra®▼ (acoramidis)
  • Kerendia®▼ (finerenone)
  • Xarelto® (rivaroxaban)
  • Women's Health
  • Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
  • Jaydess®▼ (13.5mg levonorgestrel)
  • Kyleena® (19.5mg levonorgestrel)
  • Mirena® (52mg levonorgestrel)
  • Qlaira® (estradiol valerate/dienogest)
  • Service Optimisation & Formularies
  • Risk Minimisation Materials
  • Ophthalmology
  • Oncology
  • Cardiology
  • Women's Health
  • Ophthalmology Resources
  • Oncology Resources
  • Cardiology Resources
  • Women's Health Resources
  • Ophthalmology Events & On Demand Webinars
  • Oncology Events & On Demand Webinars
  • Cardiology Events & On Demand Webinars
  • Women's Health Events & On Demand Webinars
  • Ophthalmology Learning Zone
  • Oncology Learning Zone
  • Cardiology Learning Zone
  • Women's Health Learning Zone
  • Ophthalmology Podcasts
  • Oncology Podcasts
  • Cardiology Podcasts
  • Women's Health Podcasts
closesearch
Recent Searches
      Beyonttra®▼ (acoramidis)
      Mechanism of Action
      Dosing
      Side Effects & Safety
    • More...
    Bey
    Beyonttra®▼ (acoramidis)
    Mechanism of Action
    Dosing
    Side Effects & Safety
    • Beyonttra® Resources
    • Medical Events
    • Cardiovascular Homepage
    • FAQs
    • Contact Us
    You are now leaving BayerPro

    The contents and the policies on the website you are visiting is not controlled by the BayerPRO team.
    Do you wish to continue?

    HF-Impact Banner

    Welcome to the HF-IMPACT Hub

    Our HF-IMPACT hub has been developed with the aim of improving management and prognosis through advanced cardiac training. 

    Here you can access all our Resources, Upcoming Events and On-Demand Webinars which focus on Heart Failure (HF) topics; including Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

    ATTR-CM Resources

    Navigating ATTR-CM Diagnosis
    Beyonttra®▼ (acoramidis) | Explore resources on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Beyonttra Prescribing Information
    PP-PF-CAR-GB-0060, October 2025

    On Demand Webinars

    ATTR-CM & Carpal Tunnel Syndrome
    Beyonttra®▼ (acoramidis) | Early diagnosis of ATTR-CM using carpal tunnel biopsies
    Beyonttra Prescribing Information
    PP-BEY-GB-0226, March 2026
    Cardiovascular Summit 2025 - ATTR-CM Highlights
    Explore the Key Highlights on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Beyonttra®▼ (acoramidis)
    Beyonttra Prescribing Information
    PP-BEY-GB-0085, November 2025
    CV Summit 2025 - Highlights
    Register Your Interest for 2026 Here
    Beyonttra Prescribing Information
    PP-BEY-GB-0007, November 2025

    Related Products

    Beyonttra®▼ (acoramidis) - Overview
    About Beyonttra
    Beyonttra (acoramidis) Prescribing Information
    PP-BEY-GB-0213, March 2026

    Register with BayerPRO

    To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

     

    Don’t have an account?

    PP-BEY-GB-0074 | October 2025